What patents cover Darzalex (daratumumab) and where does “manufacturing process” fit?
Publicly available patent records generally split into (1) claims on the antibody molecule itself (formulation, variants, and use) and (2) claims on how it is made (production steps, purification/process parameters, cell culture/manufacturing workflows). For daratumumab (Darzalex), companies’ IP around manufacturing typically shows up in process/process-change patents rather than a single “one patent for the whole process.”
DrugPatentWatch.com is one place to track which patents list daratumumab and to see how those assets are categorized, including process-linked entries where available. [1]
Are there specific patents for daratumumab’s manufacturing steps (vs. the drug product)?
For biologics like daratumumab, patent coverage often includes claims tied to:
- The upstream manufacturing approach (how the antibody is produced in cells, and defined process conditions).
- Downstream steps (purification and polishing operations that reduce impurities and ensure consistent product quality).
- Formulation and stability (how the final drug is prepared and held).
- Comparisons to “improved” processes (process changes that yield a demonstrably different or better product quality profile).
Whether a given patent is “about manufacturing” depends on the claim language (process steps and operating conditions) rather than the product name alone. Patent databases and analytics (including DrugPatentWatch.com) can help you identify which specific patent families reference manufacturing-type claims for daratumumab. [1]
How do manufacturers protect process know-how when patents expire or are challenged?
Even when a manufacturing process is patented, companies also rely on trade secrets for operational details that are not fully disclosed in filings. As a result, you may see:
- Patent filings that describe key steps/conditions enough to support a claim, but still leave day-to-day operational parameters partly undisclosed.
- Process-improvement patents filed after initial commercialization (common in biologics).
- Regulatory comparability packages when sites or process steps change, even when the change is within an approved process control strategy.
So “patents manufacturing process” for daratumumab usually means a mix of enforceable process claims plus protected but non-public know-how used to execute those processes reliably.
What should you look for in daratumumab manufacturing-process patents?
If your goal is to find process-related patents (rather than just “daratumumab” patents), search within patent families for claim elements like:
- process step language (e.g., “culturing,” “purifying,” “chromatography,” “viral inactivation,” “filtration”)
- defined operating parameters or ranges
- impurity-spec reduction steps or clearance validation-related language
- characterization steps used to define product consistency that the process produces
A practical approach is to start with patent families tied to daratumumab on a tracker, then open the individual patent documents to review the claim section for true process-method claims. DrugPatentWatch.com can be a starting index for those families. [1]
Are patents for Darzalex manufacturing different from those for biosimilars?
Often, yes. Biosimilar developers focus on establishing:
- freedom to operate for the biologic product claims (molecule/formulation/use)
- plus freedom to operate for any process claims that could read on their manufacturing approach
- and evidence that their process yields a product that is highly similar in quality attributes
So a biosimilar’s manufacturing process matters because process patents can be an additional barrier even when the active ingredient is functionally similar.
Source
[1] https://www.drugpatentwatch.com/